SOLICITATION NOTICE
Q -- Services regarding Donor and Recipient Telomere Length as Predictors of Outcomes after Hematopoietic Stem Cell Transplant (HSCT) in Patients with Acquired Severe Aplastic Anemia (SAA)
- Notice Date
- 7/27/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100137-AV
- Archive Date
- 8/26/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Clinical Genetics Branch (CGB) plans to procure on a sole source basis with Brigham and Women's Hospital, Inc.; 75 Francis Street; Boston, MA 02115-6110 for services regarding Donor and Recipient Telomere Length as Predictors of Outcomes after Hematopoietic Stem Cell Transplant (HSCT) in Patients with Acquired Severe Aplastic Anemia (SAA). This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be for twelve months from date of award. The Contractor shall determine telomere length (TL) by high-throughput Q-PCR in 836 samples from HSCT recipients and donors, 400 controls, and 64 samples from patients with Dyskeratosis Congenital (DC), and an additional 100 quality control samples (1400 total). The Contractor shall determine if the replicate values are in agreement and repeat duplicates, as needed (allow 5% sample replenishment). Brigham and Women's Hospital has measured TL in several epidemiological studies including breast and prostate cancers and thousands of healthy controls. Results of the quantitative PCR assay analyses will be provided in an Excel spreadsheet containing sample ID, test-date, test results (summary result and individual replicate results). Brigham and Women's Hospital and the laboratory of Dr. Immaculata DeVivo are uniquely qualified to perform this work. Traditional methods for the measuring TL including Southern blot and FISH require large amount of DNA samples (5-10 ug) and laborious, which are not suitable for large scale molecular epidemiologic studies. Brigham and Women's Hospital has validated and implemented the use of real time quantitative PCR to evaluate relative telomere length in large epidemiological studies which is critical since the assay is PCR-based, and high-throughput (384-well format on an ABI 7900HT platform). Large sets of samples are analyzed within a limited time span. In addition, it takes a small amount of DNA. Brigham and Women's has successfully completed projects for numerous researchers throughout the country including those in DCEG and published a number of papers on telomere length and risk of cancers such as prostate, breast, skin, bladder, and etc. The inter-assay coefficient of variation for their assay is extremely small, which is critical for the success to detect a small difference in TL in blood cells between cases and controls. The DNA samples used in this contract are precious since they were obtained from patients who underwent HCST for their severe acquired aplastic anemia (SAA). NCI may not have replacement for a subset of cases if they are deceased. It is imperative that the laboratory performing TL assays for this project has a demonstrated capacity for achieving success with both pre and post HCST samples. Brigham and Women's Hospital lab solely possess the expertise and resources for scientific comparability in measuring TL in a consistent and timely manner. This project is critical for the success of the ongoing efforts to identify predictors of outcomes after HCST in patients with SAA. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on August 11, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI contracting office to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist at (301) 435-3817. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-¬¬100137-AV on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100137-AV/listing.html)
- Record
- SN02219554-W 20100729/100727235912-b96916c555d4754b4b35f1ad9516feaa (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |